Lupin Limited announced that its CEO, Vinita Gupta, has been named to the prestigious 2026 CNBC Changemakers List. This recognition honors female leaders transforming business by making medicines accessible and affordable for Americans. Under her leadership, Lupin has become the third-largest generic medicine supplier in the U.S. and the world’s seventh-largest pharmaceutical company by volume.
Lupin CEO Recognized Among Business Leaders
Global pharmaceutical leader Lupin Limited announced that its Chief Executive Officer, Vinita Gupta, has been recognized on the CNBC Changemakers list of Women Transforming Business. This annual honor celebrates female executives redefining industries and driving substantial, lasting change across various sectors.
Ms. Gupta expressed that the recognition reflects the shared dedication of the entire Lupin team toward transforming hope into healing. She emphasized the importance of matching purpose with execution to achieve meaningful change.
Growth and Expansion Under Leadership
Since Ms. Gupta took leadership, Lupin’s U.S. business has experienced significant growth, positioning the company as the third-largest generic medicine supplier in the United States and the seventh-largest pharmaceutical company globally by volume.
Lupin continues to expand its focus on affordable medicine, complex generics, inhalation products, and biosimilars. A significant recent achievement includes gaining FDA approval for its first biosimilar, Pegfilgrastim, in late 2025.
Strengthening U.S. Manufacturing Footprint
Expansion in the U.S. remains a core strategic pillar for Lupin’s worldwide growth. In 2025, Ms. Gupta advanced efforts to strengthen domestic pharmaceutical manufacturing through a reshoring initiative. This included announcing plans for a new state-of-the-art inhalation facility in Coral Springs, Florida, intended to produce respiratory products like Albuterol. This expansion aims to reinforce medicine security and improve patient access to critical treatments in the United States.
Event Details
Honorees, including Ms. Gupta, will be celebrated at the CNBC Changemakers Summit scheduled for April 16th in New York.
About Lupin
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, distributing products across over 100 markets. The company specializes in branded and generic formulations, complex generics, biotechnology, and active pharmaceutical ingredients (APIs). Lupin maintains a robust infrastructure with 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce exceeding 24,000 professionals.
Source: BSE
